IBA FY21 Trading Update

PROFITABILITY ACROSS ALL BUSINESS LINES

Louvain-la-Neuve, Belgium, 1 February 2022 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, today provides a trading update ahead of the Company’s full-year results on 24 March 2022.

IBA will report FY21 Group sales in line with the prior year, with a positive REBIT and net profit at Group level and profitability across all business lines.

• High order intake across all business lines
  • Proton Therapy saw a continued revival in activity with five systems (nine rooms) sold in Asia, Europe and the US, compared with two systems sold in the prior year
  • Other Accelerators had another excellent year with more than 30 systems sold, up from 17 systems last year
  • The Dosimetry business has continued to perform well with order intake in line with the prior year
• Equipment and Services backlog at a new all-time high of EUR 1.2 billion
• Highly active pipeline, particularly in the US and Asia, with continuing momentum providing significant visibility for 2022 and beyond
• All time high net cash position of EUR 130.3 million (unaudited) at year end, providing the business a solid foundation to progress its strategic objectives

Olivier Legrain, Chief Executive Officer of IBA, commented: “IBA performed exceptionally well in 2021, with a high order intake and profitability demonstrated across all business lines. IBA’s market leading product offerings in proton therapy, other accelerators, radiopharmaceuticals and dosimetry have driven this momentum, which continued to build throughout the year. We have entered 2022 in a strong position with an active global pipeline for all businesses, particularly in the US and Asia. Our record high cash position provides us with a solid foundation from which we can explore other growth areas such as theranostics, whilst achieving our goal of long-term sustainable profitability.”

IBA will publish its consolidated results for the full year 2021 on Thursday, 24 March 2022 at 7am CET.

In addition to the press release, Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a conference call and webcast, conducted in English, to present the 2021 full year results, followed by a Q&A session.

Conference Call Information
This conference call will be held on Thursday, 24 March 2022 at 3pm CET / 2pm GMT / 10am EDT / 7am PDT as a Teams webinar and can be accessed online on this link.
If you would like to join by phone only, please dial (Phone conference ID 913 259 995#):

Belgium:                     +32 2 890 97 20
UK:                             +44 20 3321 5200
NL:                              +31 20 708 6901
LU:                              +352 27 87 00 02
US:                             +1 347-991-7591
FR:                              +33 1 70 99 53 51

The presentation will be available on IBA’s investor relations website and on:
https://www.iba-worldwide.com/content/iba-full-year-2021-results-press-release-and-web-conference  shortly before the call.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.

Shareholder’s Agenda
Full Year Results                                                       24 March 2022
Business Update First Quarter 2022                        19 May 2022
General Assembly                                                     8 June 2022
Half Year 2022 Results                                             31 August 2022
Business Update Third Quarter 2022                       17 November 2022

***Ends***

About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,500 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com

Consilium Strategic Communications
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700
IBA@consilium-comms.com

Attachment

• 220201-IBA_2021_Trading_Update-EN